New combo therapy aims to shrink liver tumors in hard-to-treat patients
NCT ID NCT05441475
First seen Mar 01, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tests a new drug (ABSK-011) combined with atezolizumab or standard care in about 118 people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. Participants must have a specific genetic marker (FGF19 overexpression) and have had little or no prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Hubei, Shanghai Municipality, 430030, China
Conditions
Explore the condition pages connected to this study.